Selecta Gets Third Collaboration With SAIC Malaria Subcontract
By Tom Wall
Wednesday, August 31, 2011
Selecta Biosciences Inc. has scored its third significant collaboration in the past 12 months with a subcontract from Science Applications International Corp. (SAIC), of McLean, Va., to develop a targeted synthetic vaccine particle (tSVP) product for malaria.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.